<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20220810161200+02'00'</creation_date><modification_date>D:20220810161200+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-3-22-2687_o_a_dec_0.pdf</pdf_file></head><body><section><header>en  
  en</header><p>european 
 commission</p><p>
 brussels, 10.8.2022</p><p>c(2022) 5917 final</p></section><section><header>commission implementing decision of 10.8.2022 
 relating to the designation of &quot;clarithromycin, clofazimine, rifabutin&quot; as an orphan 
 medicinal product under regulation (ec) no 141/2000 of the european parliament and 
 of the council</header><p>(text with eea relevance) (only the english text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decision of 10.8.2022 
 relating to the designation of &quot;clarithromycin, clofazimine, rifabutin&quot; as an orphan 
 medicinal product under regulation (ec) no 141/2000 of the european parliament and 
 of the council</header><p>(text with eea relevance) (only the english text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 141/2000 of the european parliament and of the council 
 of 16 december 1999 on orphan medicinal products
 1, and in particular the first sentence of article 5(8) thereof, 
 having regard to the application submitted by regintel limited on 18 may 2022 under article 
 5(1) of regulation (ec) no 141/2000, 
 having regard to the favourable opinion of the european medicines agency, drawn up on 14 
 july 2022 by the committee for orphan medicinal products and received by the commission 
 on 22 july 2022, 
 whereas: 
 (1) 
 the application submitted by regintel limited concerning the medicinal product 
 “clarithromycin, clofazimine, rifabutin” was validated on 14 june 2022 under article 
 5(4) of regulation (ec) no 141/2000. 
 (2) 
 &quot;clarithromycin, clofazimine, rifabutin&quot; meets the designation criteria referred to in 
 article 3(1) of regulation (ec) no 141/2000. 
 (3) 
 the application should therefore be accepted, 
 has adopted this decision: 
 article 1 the medicinal product “clarithromycin, clofazimine, rifabutin” is designated as an orphan medicinal product for the indication: treatment of nontuberculous mycobacterial lung disease. 
 it shall be entered in the community register of orphan medicinal products under number 
 eu/3/22/2687.</p><p>
 1 oj l 18, 22.1.2000, p.1.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>article 2 the european medicines agency shall make available to all interested parties the opinion of the committee on orphan medicinal products referred to in this decision. 
 article 3 this decision is addressed to regintel limited, templetown, carlingford a91 x097, co. louth, ireland. 
 done at brussels, 10.8.2022</p><p>for the commission</p><p>
 sandra gallina</p><p>
 director-general</p></section></body></xml>